This article is about a new method for transglutaminase mediated site specific conjugation using targeted peptide sequences engineered into the heavy chain of the antibody.
They demonstrated the effectiveness on trastuzumab and showed efficient conjugation.
Efficient Site‐Specific Antibody‐Drug Conjugation by Engineering of a Nature‐Derived Recognition Tag for Microbial Transglutaminase
This sounds strikingly similar to Catalent's (Formerly Redwood Biosciences) SMARTag technology. But either way, more conjugation technology is always a good thing.
No comments:
Post a Comment